MedShieldFL-a privacy-preserving hybrid federated learning framework for intelligent healthcare systems

8.5

来源： Nature 关键字： AI brain science

发布时间： 2025-12-05 03:32

摘要：

MedShieldFL is a pioneering hybrid federated learning framework designed for intelligent healthcare systems, specifically targeting brain tumor classification. By employing homomorphic encryption and generative adversarial networks (GANs), it effectively addresses data privacy concerns while enhancing classification accuracy. The framework allows multiple healthcare institutions to collaborate on model training without sharing sensitive patient data, thus ensuring compliance with privacy regulations. Test results indicate that MedShieldFL can classify brain tumors with an accuracy ranging from 93% to 96%, showcasing its potential for real-world clinical applications.

原文：查看原文

价值分投票

评分标准

新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。评分越高，表示该新闻的价值越大，越值得关注。

价值维度分析

domain_focus

1.0分+1.0分+1.0分

business_impact

0.5分+0.5分

scientific_rigor

1.5分+1.5分

timeliness_innovation

1.5分+1.5分

investment_perspective

2.5分+2.5分

market_value_relevance

1.0分+1.0分

team_institution_background

0.5分+0.5分

technical_barrier_competition

1.0分+1.0分

关键证据

MedShieldFL achieves 93% to 96% accuracy in brain tumor classification.

The framework integrates GAN-based data augmentation to address class imbalance.

Homomorphic encryption ensures secure model aggregation while maintaining data privacy.

真实性检查

否

AI评分总结

MedShieldFL is a pioneering hybrid federated learning framework designed for intelligent healthcare systems, specifically targeting brain tumor classification. By employing homomorphic encryption and generative adversarial networks (GANs), it effectively addresses data privacy concerns while enhancing classification accuracy. The framework allows multiple healthcare institutions to collaborate on model training without sharing sensitive patient data, thus ensuring compliance with privacy regulations. Test results indicate that MedShieldFL can classify brain tumors with an accuracy ranging from 93% to 96%, showcasing its potential for real-world clinical applications.